Gentil M A, Carriazo A, Pavón M I, Rosado M, Castillo D, Ramos B, Algarra G R, Tejuca F, Bañasco V P, Milan J A
Andalusian Renal Patients Registry, Office of Information and Informatics, Sevilla, Spain.
Nephrol Dial Transplant. 1991;6(6):444-51. doi: 10.1093/ndt/6.6.444.
We compared the survival of 842 patients on centre haemodialysis to 272 patients on continuous ambulatory peritoneal dialysis (CAPD). All patients selected had begun treatment between 1 January 1984 and 30 June 1988 and were from six centres which participate in a regional renal patients registry. Patients on CAPD were older and had a greater proportion of diabetes and other associated diseases. Age, diabetes, and cardiovascular diseases were associated with a shorter survival on treatment in all the patients studied. Without adjustment for risk factors, patient 3-year survival was higher in centre haemodialysis than in CAPD, 80% versus 64% respectively. However, no significant differences could be shown in the survival rates of the two treatment modalities after accounting for the heterogeneity of the patients in the two groups, either by stratification or by multivariate analysis (Cox). Age was the main predictive factor for CAPD patient survival, while the influence of diabetes and cardiovascular diseases was less clear. Technique survival was much better in centre haemodialysis (94% versus 56% in CAPD, 3-year survival). Older age and diabetes mellitus were associated with a greater risk of switching from centre haemodialysis to CAPD and a trend to retain those patients on CAPD.
我们将842例接受中心血液透析的患者与272例接受持续性非卧床腹膜透析(CAPD)的患者的生存率进行了比较。所有入选患者均于1984年1月1日至1988年6月30日开始治疗,来自参与区域肾脏患者登记处的六个中心。接受CAPD治疗的患者年龄更大,糖尿病及其他相关疾病的比例更高。在所有研究患者中,年龄、糖尿病和心血管疾病与治疗期间较短的生存期相关。在未对危险因素进行校正的情况下,中心血液透析患者的3年生存率高于CAPD患者,分别为80%和64%。然而,在对两组患者的异质性进行校正后,无论是通过分层分析还是多变量分析(Cox法),两种治疗方式的生存率均无显著差异。年龄是CAPD患者生存的主要预测因素,而糖尿病和心血管疾病的影响则不太明确。中心血液透析的技术生存率要好得多(3年生存率,中心血液透析为94%,CAPD为56%)。年龄较大和患有糖尿病与从中心血液透析转为CAPD的风险增加相关,且有将这些患者保留在CAPD治疗的趋势。